Sigrun Erkens-Schulze
Overview
Explore the profile of Sigrun Erkens-Schulze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buck S, Van Hemelryk A, de Ridder C, Stuurman D, Erkens-Schulze S, van t Geloof S, et al.
Mol Cancer Ther
. 2023 Nov;
23(5):711-720.
PMID: 38030379
Resistance to taxane chemotherapy is frequently observed in metastatic prostate cancer. The androgen receptor (AR) is a major driver of prostate cancer and a key regulator of the G1-S cell-cycle...
2.
Van Hemelryk A, Erkens-Schulze S, Lim L, de Ridder C, Stuurman D, Jenster G, et al.
Cells
. 2023 Jul;
12(10).
PMID: 37408211
Tumor organoids have been pushed forward as advanced model systems for in vitro oncology drug testing, with the eventual goal to direct personalized cancer treatments. However, drug testing efforts suffer...
3.
Van Hemelryk A, Tomljanovic I, de Ridder C, Stuurman D, Teubel W, Erkens-Schulze S, et al.
Cells
. 2022 Nov;
11(22).
PMID: 36429059
Castration-resistant prostate cancer (CRPC) remains an incurable and lethal malignancy. The development of new CRPC treatment strategies is strongly impeded by the scarcity of representative, scalable and transferable preclinical models...
4.
Van Hemelryk A, Mout L, Erkens-Schulze S, French P, van Weerden W, van Royen M
Biomolecules
. 2021 Nov;
11(11).
PMID: 34827570
Organoid-based studies have revolutionized in vitro preclinical research and hold great promise for the cancer research field, including prostate cancer (PCa). However, experimental variability in organoid drug testing complicates reproducibility....
5.
Mout L, van Dessel L, Kraan J, de Jong A, Neves R, Erkens-Schulze S, et al.
Eur J Cancer
. 2021 May;
150:179-189.
PMID: 33932725
Background: Circulating tumour cell (CTC)-derived organoids have the potential to provide a powerful tool for personalised cancer therapy but are restrained by low CTC numbers provided by blood samples. Here,...
6.
Mout L, Moll J, Chen M, de Morree E, de Ridder C, Gibson A, et al.
Br J Cancer
. 2020 Sep;
123(12):1715-1719.
PMID: 32989230
Androgen receptor (AR) signalling drives neoplastic growth and therapy resistance in prostate cancer. Recent clinical data show that docetaxel combined with androgen deprivation therapy improves outcome in hormone-sensitive disease. We...
7.
Langeback A, Bacanu S, Laursen H, Mout L, Seki T, Erkens-Schulze S, et al.
Sci Rep
. 2019 Dec;
9(1):19384.
PMID: 31852908
The use of taxanes has for decades been crucial for treatment of several cancers. A major limitation of these therapies is inherent or acquired drug resistance. A key to improved...
8.
Zhang W, van Weerden W, de Ridder C, Erkens-Schulze S, Schonfeld E, Meijer T, et al.
Prostate
. 2018 Dec;
79(4):390-402.
PMID: 30520109
Background: In vitro models of prostate cancer (PCa) are not always reliable to evaluate anticancer treatment efficacy. This limitation may be overcome by using viable tumor slice material. Here we...
9.
Davies E, Dong M, Gutekunst M, Narhi K, van Zoggel H, Blom S, et al.
Sci Rep
. 2015 Dec;
5:17187.
PMID: 26647838
Precision-cut slices of in vivo tumours permit interrogation in vitro of heterogeneous cells from solid tumours together with their native microenvironment. They offer a low throughput but high content in...
10.
Kumagai J, Hofland J, Erkens-Schulze S, Dits N, Steenbergen J, Jenster G, et al.
Prostate
. 2013 Sep;
73(15):1636-50.
PMID: 23996639
Background: Despite an initial response to hormonal therapy, patients with advanced prostate cancer (PC) almost always progress to castration-resistant disease (CRPC). Although serum testosterone (T) is reduced by androgen deprivation...